DIA 48th Annual Meeting
Click here to go to the previous page
Application of Quality of Evidence Assessment Tools to the Evaluation of Observational Pharmacoepidemiologic Studies
Track
:
Track 13: Health Economics and Outcomes (HEO)/Comparative Effectiveness Research (CER)/Health Technology Assessment (HTA)
Program Code:
169
Date:
Monday, June 25, 2012
Time:
3:30 PM to 5:00 PM
EST
CHAIR
:
George Neyarapally, FDA, United States
PRESENTER
(S):
Tarek Hammad, FDA, United States Nancy Dreyer, Outcome, United States Alexander Walker, World Health Information Science Consultants (WHISCON), United States
George Neyarapally, FDA, United States
Description
The assessment of the benefits and risks associated with drug exposure take into consideration data from pharmacoepidemiologic studies and from other data streams. This forum will address potential applications of quality assessment tools to the evaluation of pharmacoepidemiologic safety studies and the development of a tool to assess observational CER studies. A panel will discuss these issues and their implications.
Learning Objectives:
Discuss issues pertaining to the availability and potential application of quality assessment tools for evaluating pharmacoepidemiologic safety studies
Explain the development of a tool for the assessment of epidemiologic comparative effectiveness studies under the GRACE (Good Research for Comparative Effectiveness) initiative.
Learning Objectives:
Discuss issues pertaining to the availability and potential application of quality assessment tools for evaluating pharmacoepidemiologic safety studies
Explain the development of a tool for the assessment of epidemiologic comparative effectiveness studies under the GRACE (Good Research for Comparative Effectiveness) initiative.
This session is a part of:
Handout Online
